← Leaderboards
Norberto Gonzalez-Juarbe
J. Craig Venter Institute, Inc.
$4,233,111
Attributed
$5,252,450
Total exposure
3
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.6M · FY2020–25$2M$1.5M$1M$500K$0
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$5,252,450 · 3
By mechanism
R01$4,710,274 · 2
R21$542,176 · 1
Top collaborators
- Alexey V Fedulov3 shared
Most similar at J. Craig Venter Institute, Inc.
Same institution · by research overlap
- Alexey V Fedulov$3,915,404
- Lauren Marie Oldfield$938,847
Others in their field
Other Emerging Leaders on “Response”
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$195,683,539
- Kimberly Smith · Ppd Development Lp$115,671,664
- Paul F Gallagher · Woods Hole Oceanographic Institution$92,619,872
- Kevin Urdahl · Seattle Children'S Hospital$84,741,409
- Marlene Ann Cooper · Harvard University D/B/A Harvard School Of Public Health$71,439,892
- Ted Ross · University Of Georgia$70,992,558
Research focus
ResponseGenerationsPredispositionLeadAntibioticsInflammationAnimal ModelCellsLungOrganismAnimalsAntibodiesIn VitroImmunogenicIncidenceIn VivoElderlyAntimicrobial ResistanceDendritic CellsAntigensCessation Of LifeDisadvantagedImmunityAntibody Response
Grant awards (8)
Endolysins as tools to eradicate pneumococcal biofilms and development ofprotective immunity$879,588
R01 · FY2025 · AI · contact PI
Endolysins as tools to eradicate pneumococcal biofilms and development ofprotective immunity$890,998
R01 · FY2024 · AI · contact PI
Endolysins as tools to eradicate pneumococcal biofilms and development of protective immunity$901,010
R01 · FY2023 · AI · contact PI
Microbiome in Asthma Induced by Environmental Particle Exposure$673,348
R01 · FY2023 · ES · contact PI
Microbiome in Asthma Induced by Environmental Particle Exposure$676,358
R01 · FY2022 · ES · contact PI
Microbiome in Asthma Induced by Environmental Particle Exposure$688,972
R01 · FY2021 · ES · contact PI
Development of novel protein-based vaccine formulations to prevent pneumococcal colonization and disease$283,588
R21 · FY2021 · AI · contact PI
Development of novel protein-based vaccine formulations to prevent pneumococcal colonization and disease$258,588
R21 · FY2020 · AI · contact PI